Congruence is building a pipeline of best-in-class and first-in-class oral small molecule correctors and allosteric modulators directed to genetically validated, difficult-to-drug proteins implicated in diseases spanning a variety of therapeutic areas, including: metabolism, neurology, immunology, oncology and other rare diseases.